Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study-Reference-Cited by-同舟云学术

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study

Published:2023-08 Issue: Volume:62 Page:102136
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Lu Nian^ORCID,Jiang Yao-Fei,Xia Wei-Xiong,Huang Ying,Xie Chuan-Miao,Xu Cheng,Ye Yan-Fang,Liu Guo-Ying,Bei Wei-Xin,Ke Liang-Ru,Li Wang-Zhong,Zhang Cheng,Wang Xin^ORCID,Liu Qin,Chen Xi,Chen Zi-Xiong,Xie Changqing^ORCID,Liang Hu^ORCID,Xiang Yan-Qun

Publisher

Elsevier BV

Subject

General Medicine

Reference45 articles.

1. Nasopharyngeal carcinoma;Chen;Lancet,2019

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

3. Nasopharyngeal carcinoma: an evolving paradigm;Wong;Nat Rev Clin Oncol,2021

4. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities;Sun;Radiother Oncol,2014

5. NCCN Guidelines® insights: head and neck cancers, Version 1.2022;Caudell;J Natl Compr Canc Netw,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

2. Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer;Cancer Medicine;2024-07

3. Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma;Current Molecular Pharmacology;2024-05-17

4. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy;Scientific Reports;2024-01-20